Product category:
Contract research
News Release from: Pharmaceutical Profiles
Edited by the Laboratorytalk Editorial
Team on 02 August 2002
New early phase drug development service
Biodistribution service aimed at diagnostic and therapeutic radio pharmaceuticals for the nuclear medicine market
Pharmaceutical Profiles - an early phase drug development services company that utilises sophisticated medical imaging techniques to evaluate pharmaceutical product performance in man - recently launched its biodistribution services with an exhibit at the 49th annual Society of Nuclear Medicine Meeting in Los Angeles, USA The ccompany also plans to exhibit later in August/September at the European Association of Nuclear Medicine Congress in Vienna, Austria, to complete the launch in Europe
This article was originally published on Laboratorytalk on 30 May 2003 at 8.00am (UK)
Related stories
Human absorption studies webcast
The role of absorption studies in humans is to be examined by one of the pharmaceutical industry's leading authorities in oral drug delivery in a web-based seminar
Added value for pharmacokinetic studies
Service designed to maximise the data obtained from 'standard' clinical studies in healthy volunteers has been launched by an early phase drug development specialist
Biodistribution investigations determine the safety and effectiveness of radiopharmaceuticals in phase I/IIa clinical trials.
Radiopharmaceuticals are used in diagnostic imaging and therapeutic applications in nuclear medicine.
There are an increasing number of new radiopharmaceutical products in development, all of which must pass rigorous testing to determine their efficacy and safety.
Further reading
Human microdosing points the way forward
A microdose is 100 times below the level calculated to yield a pharmacological effect or 100 micrograms, whichever is the lower
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
Biodistribution investigations determine the safety and effectiveness of radiopharmaceuticals in phase I/IIa clinical trials.
Pharmaceutical Profiles's biodistribution division is well placed to service this growing market, leveraging its established experience in the area of gamma scintigraphy.
The recent investment in a state-of-the-art dual-headed gamma camera, as well as the hiring of key personnel, has enabled Pharmaceutical Profiles to offer comprehensive biodistribution study services to pharmaceutical companies with radiopharmaceuticals in phase I/IIa development.
Pharmaceutical Profiles is the first contract research company to offer a tailor-made scientific, clinical and regulatory biodistribution service and it believes there are significant advantages in assessing new diagnostic agents in such a commercial environment.
Recently revised FDA guidelines have sought to clarify and expand the scope of early phase clinical trials required for such products.
These regulations place increased emphasis on the pharmacological and toxicological response of both the radionuclide and the ligand (carrier) components, in addition to the evaluation of the radiation absorbed dose and biodistribution.
"Despite revisions to the FDA regulations in this area, there is much confusion and uncertainty with in the design of early phase clinical trials", explained Dennis Heller, vice president, biodistribution business development for Pharmaceutical Profiles, "Our experience over the past several years in assisting clients with the optimisation of clinical trial objectives, to address the concerns set forth by regulatory agencies such as the FDA, sets us apart from other centres" explained Dr Heller.
"For many companies this experience is often the key to initiating a successful clinical programme." In recent years, the trend has been for the design of very comprehensive Phase I/IIa studies with multiple objectives to address safety, pharmacokinetics and biodistribution.
Historical providers such as academic research centres and nuclear medicine departments within hospitals will be increasingly less able to manage these types of studies due to their complexity and demand for dedicated resources.
• Pharmaceutical Profiles: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
